Drug Trial Radar · NCT07445906
A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Mar 15, 2026
Primary completion
Dec 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous injection of RG002C0106 between trial participants with normal renal function and those with mild to moderate renal impairment.
Conditions
- Renal Impairments
- IgA Nephropathy (IgAN)
Interventions
RG002C0106Drug
Subcutaneous (SC) single dose 200mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Calculate the pharmacokinetic (PK) parameters:CmaxTime frame: From enrollment to the end of treatment at 4 days
- Calculate the pharmacokinetic (PK) parameters:TmaxTime frame: From enrollment to the end of treatment at 4 days
- Calculate the pharmacokinetic (PK) parameters:AUC0-12h , AUC0-24h , AUC0-t, AUC0-∞Time frame: From enrollment to the end of treatment at 4 days
- Calculate the pharmacokinetic (PK) parameters:t½Time frame: From enrollment to the end of treatment at 4 days
- Calculate the pharmacokinetic (PK) parameters:Vd/FTime frame: From enrollment to the end of treatment at 4 days
- Incidence of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drug.Time frame: up to 169 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
No. 50 in Huatuo Road, Daxing District
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.